Skip to content

Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population

· 0 citations · 68 references

TL;DR

PAI-1 level increased exponentially as the number of diagnostic criteria increased linearly as the number of diagnostic criteria increased linearly, supporting the conclusion that MetS components have a joint effect that is stronger than their additive contributions.

View source

Similar papers

Open access 2026

High levels of MCP-1 in menopause and their relationship with components of the metabolic syndrome.

BACKGROUND The menopause stage involves a significant reduction in circulating estrogen levels, resulting in notable changes to the cardiovascular, metabolic, bone, and immune systems. Monocyte chemoattractant protein-1 (MCP-1) is strongly associated with cardiovascular diseases and obesity. However, it is crucial to e...

Lourdes Basurto, Violeta Castro-Leyva, S. Vega-García et al. · 0 citations
Open access Sep 2026

Prevalence of Elevated Lipoprotein(a) and Its Association with Cardiovascular Disease in Patients with Overweight and Obesity in Argentina

Elevated Lp(a) was independently associated with IHD across all BMI categories, without significant interaction between BMI and Lp(a), and these findings support consideration of Lp(a) assessment across the BMI spectrum.

Ezequiel Forte, M. Arrupe, Leonardo Bufi et al. · 0 citations
Open access Sep 2026

Associations of Elevated Lipoprotein(a) with C-Reactive Protein and Type 2 Diabetes in a Multiethnic Population

Findings support the emerging concept that Lp(a) may function as a molecular-inflammatory mediator potentially contributing to residual cardiovascular risk and highlight the importance of incorporating Lp(a) assessment into cardiometabolic risk stratification, particularly in high-risk populations.

Mohammad G. Qaddoumi, A. Albatineh, I. Alkhairi et al. · 0 citations
Review Sep 2026

SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Managing Metabolic Syndrome Among Patients with Type 2 Diabetes Mellitus - A Narrative Review.

SGLT-2 inhibitors and GLP-1 receptor agonists form an effective strategy for managing MetS in the context of T2DM and their broad effects on metabolism and well-known heart and kidney benefits make them vital parts of modern treatment for cardiometabolic conditions.

Hadeeqah Zayaan Riaz Ahamed, Sulthan Al Rashid, Rajkapoor Balasubramanian et al. · 0 citations
Open access Aug 2026

Association Between the Number of Metabolic Syndrome Components and Markers of Subclinical Vascular Damage: A Retrospective Cross-Sectional Study

The results do not support the use of a simple count of MetS components as an indicator of subclinical cardiovascular dysfunction related to atherosclerosis and AS, and most associations were explained by confounding variables.

M. Starzak, Grzegorz K. Jakubiak, N. Pawlas et al. · 1 citation
Open access Oct 2026

High lipoprotein(a) levels in patients with very high cardiovascular risk: incidence and association with other risk factors

Lipoprotein(a) (Lp(a)) is a significant independent cardiovascular risk factor (CVR) associated with the development of atherosclerotic cardiovascular disease (CVD), heart failure, atrial fibrillation, and increased overall and cardiovascular mortality. The aim of the study: to assess the incidence of elevated Lp(a)...

O. Timoshchenko, O. V. Tsygankova, E. Shakhtshneider et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.